InDex Pharmaceuticals conducts PK study with cobitolimod

August 19, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will conduct a clinical pharmacokinetic study (PK study) with cobitolimod in Sweden. The Swedish Medical Products Agency has given approval to start the study.

InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis

March 30, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the phase III study CONCLUDE. The study will evaluate the efficacy and safety of the drug candidate cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.

Investor contact

Peter Zerhouni
Peter Zerhouni
+46 8 122 038 50